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Abstract 
 
OBJECTIVE: To determine if preeclampsia (PE) and intrauterine growth restriction 
(IUGR) is associated with differing levels of angiogenic and anti-angiogenic growth 
factors in both maternal and fetal circulation and the effect of  heme oxygenase-1 
(HO-1) and honokiol, an AKT phosphorylation inhibitor, on endothelial cells (EC) on 
these anti-angiogenic growth factors. 
 DESIGN: 1
st
 test ; Nested case-controlled plasma samples from 165 pregnant patients 
assayed for soluble vascular endothelial growth factor 1 (sVEGFR-1) soluble 
endoglin (sEng), vascular endothelial growth factor (VEGF) and placental growth 
factor (PlGF) in Spain during 2001-2007. 2
nd
 test; knockdown of HO-1 on EC and 
assayed to observe the effects on sVEGFR-1 levels released. 3
rd 
test; 24 hour 
treatment to honokiol, an extract from the magnolia tree, on endothelial cells to 
observe the effect on sVEGFR-1 and sEng release.  
RESULTS: In the PE specimens, maternal sVEGFR-1 levels increased more than 3-
fold compared with gestational controls, fetals levels remained unchanged. The levels 
of sEng, and PlGF did not significantly change and the levels of VEGF 8-fold more 
than the controls. Free sVEGFR-1 was found to be in 4-fold excess in the PE state 
compared to the gestational control. siRNA of HO-1 was found to cause an elevation 
in VEGF activated sVEGFR-1 release. Honokiol was found to decrease VEGF 
activated sVEGFR-1 release with increasing concentration and increase sEng release 
in the presence of various growth factors.  
CONCLUSION: There is an excess of sVEGFR-1 present in PE. Heme oxygenase 1 
mediates sVEGFR-1 release and honokiol decreases sVEGFR-1 release from EC.  
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Preeclampsia 
 
Preeclampsia (PE) is a pregnancy-specific disorder affecting 3-5% of all pregnancies. 
It is associated with poor placental function due to insufficient endovascular invasion 
of maternal vessels to the protruding villi of the placenta (Friedman and Fox, 1976). 
The precise mechanism underlying PE is unknown. Women who have PE are at risk 
of developing cardiovascular diseases in later life (Bilhartz et al., 2011). Normal 
women who suffer from PE return to normal following delivery of the placenta 
suggesting it is a placental driven syndrome.  
 
PE is characterised by the onset of proteinuria and hypertension (140/90 mmHg) 
during the third trimester of pregnancy and severe PE can result in small for 
gestational age babies (SGA). The clinical onset of PE is usually asymptomatic and 
severe PE can result in progressive forms of PE such as eclampsia and HELLP 
syndrome (haemolysis, elevated liver enzymes and low platelets). The only current 
way of alleviating the symptoms is premature delivery in order to preserve maternal 
health. Early delivery often has consequences on the health of the newborn, 
particularly before 32 weeks gestation. On the other hand, delay to allow for fetal 
respiratory maturity, in utero, increases maternal risk factors (Ahmed, 2011). PE 
condition can range from mild to severe and sometimes mild cases are not included in 
official statistics although over 63,000 maternal deaths worldwide are due to 
preeclampsia (Noris et al., 2005). PE is associated with placental hypo-perfusion, 
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which can result in intrauterine growth restriction (IUGR) (Maynard and Hubbell, 
2005).  
 
Risk Factors 
 
Previous studies have shown a genetic link attached to PE (Esplin et al., 2001) 
showing that a first degree relation increases PE risk by up to 4 fold. Although this is 
a maternal disorder, due to the placenta being a product of both parents, a paternal 
history of PE can also increase the risk of PE (Esplin et al., 2001). 
 
A medical history of hypertension, diabetes, impaired renal function and obesity have 
been shown to increase the risk of PE (Duckitt and Harrington, 2005). Smoking 
during pregnancy has been shown to decrease incidence of PE (England et al., 2002). 
 
Neonatal morbidity is usually as a consequence of early delivery and low birth weight 
and HELLP syndrome has been linked with a 15% incidence of prenatal mortality due 
to premature delivery (Roelofsen et al., 2003). PE occurs only in the presence of a 
placenta and not necessarily in the presence of a fetus (as is the case in a hypatidiform 
mole) and all symptoms are alleviated following delivery of the placenta (Kanter et 
al., 2010).  
 
Placental Vascular Remodeling 
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Early in placentation, the extra villous cytotrophoblasts invade the maternal uterine 
spiral arteries transforming the maternal vascular endothelial cells, medial elastic 
tissue, smooth muscle and the neural tissue such that very little smooth muscle 
remains creating an environment of low blood flow resistance allowing the increase in 
uterine blood flow through dilated tubes lined by cytotrophoblasts needed to sustain 
the fetus during pregnancy (Brosens et al., 1972). In PE this invasion occurs either 
superficially or not at all. This shallow invasion results in an inadequate vascular 
remodelling, which does not correlate with the fetal blood flow and nutrient demands. 
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Figure 1: The differences between normal and PE placental invasion. In the 
impaired preeclamptic state, invasion of the spiral arteries is shallow, and they remain 
small, highly resistant vessels (Lam et al., 2005). 
During normal placentation, the invasive cytotrophoblasts down regulate the 
epithelial-type adhesion molecules. In PE, these cell surface integrins and adhesion 
molecules fail to sufficiently invade the maternal myometrial spiral arteries (Zhou et 
al., 2002). Animal models of PE can be induced by the constriction of uterine blood 
flow suggesting that PE is as a result of placental ischaemia (Sane et al., 2004).  
 
PE is more common at high altitude suggesting it is hypoxia driven (Zamudio et al., 
1995). It has been suggested that placental hypoxia/ischaemia results in the release of 
products into the maternal circulation that then initiates the maternal circulation into 
pathophysiological changes resulting in PE. 
 
Vascular Growth Factors and Preeclampsia 
 
The effect of a low oxygen environment is thought to be a major regulator of the 
balance between VEGF and PlGF function. Khaliq et al. showed that hypoxia down 
regulates PlGF mRNA in a term trophoblast-like choriocarcinoma cell line (Khaliq et 
al., 1999) and that PlGF-2 inhibited growth of endothelial cells and proliferation 
(Khaliq et al., 1999). 
 
Trophoblasts produce large quantities of sVEGFR-1 (Clark et al., 1996). Maynard et 
al. demonstrated that overexpression of sVEGFR-1 lead to PE like symptoms 
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including hypertension, proteinuria, glomerular endotheliosis, suggesting an important 
role for sVEGFR-1 and the angiogenic factors VEGF and PlGF (Maynard et al., 
2003). sVEGFR-1 is elevated in patients with PE as early as 10 weeks into pregnancy 
in comparison to the gestationally matched control patients (Maynard et al., 2003).  
 
Angiogenesis is a natural adaptive mechanism to redress the imbalance created by a 
reduction in oxygen tension and nutrient demand but in cancer induction of 
angiogenesis is unwanted and it is the metastatic response of the tissue to survive. 
 
VEGF and VEGF Receptors 
 
Loss of a single VEGF allele renders an embryonically lethal phenotype due to 
multiple defects in the cardiovascular system (Carmeliet et al., 1996, Ferrara et al., 
1996). Structurally, members of the VEGF family belong to the endothelial cell 
platelet derived growth factor (PDGF) super-gene family. Various isoforms of VEGF-
A include VEGF121 (Goerges and Nugent, 2004), VEGF145, VEGF165, VEGF183, 
VEGF189 and VEGF206. Other members of the VEGF super-family are VEGF-B, 
VEGF-C, VEGF-D, VEGF-E, PlGF-1 (placental growth factor, also abbreviated to 
PlGF), PlGF-2 and PlGF-3. VEGF-A145 and VEGF183 are relatively rare 
physiologically (Neufeld et al., 1999). 
 
VEGF expression is regulated by changes in oxygen tension, via HIF-1 (Semenza, 
2001). PlGF is significantly expressed by endothelium; however has little or no direct 
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mitogenic or permeability-enhancing activities although it does potentiate the effects 
of low concentrations of VEGF (Park et al., 1994). 
 
The VEGF family of ligands exercise their direct cellular effects via three dimeric, 
tyrosine kinase receptors, namely VEGFR-1 (Fms-like tyrosine kinase-1, also sFlt-1), 
KDR (kinase insert-containing domain receptor, also VEGFR-2, Flk-1 (fetal liver 
kinase-1) and Flt-4 (VEGFR3). Structurally, VEGFR-1 and VEGFR-2 have seven 
immunoglobulin-like domains in the extracellular region, a single trans-membrane 
region and a consensus tyrosine kinase sequence that is interrupted by a kinase-insert 
domain (Shibuya et al., 1990, Terman et al., 1991). The figure below shows the 
VEGF family receptors and co-receptors, and the ligands that bind and activate them. 
 
 
Figure 2 VEGF family and ligands.  
Islam Afzal    
18 
 
The VEGF family has a number of different receptors and ligands, which bind with 
differing affinity to the receptors. Soluble VEGFR1 (sVEGFR-1) is anti angiogenic 
having a higher affinity to VEGF than the VEGFR-2 receptor. There is also a 
VEGF:PLGF heterodimer (not shown). VEGFR-3 has a more dominant role in 
lymphangiogenesis. 
  
VEGFR3 and its ligands VEGF-C and VEGF-D, which also bind and activate 
VEGFR-2 but only in processed forms, are mainly involved in lymph angiogenesis 
(Jeltsch et al., 1997, Makinen et al., 2001, Veikkola et al., 2001). VEGFR-2 is 
considered to be the receptor most crucial for VEGF-induced mitogenicity, whilst 
VEGFR-1 has a less clear function. VEGFR-1 has a higher affinity for VEGF than 
VEGFR-2 but it also has a much lower tyrosine kinase activity therefore signalling 
function (Shibuya, 2006) has been difficult to interpret, however, it may have a role in 
endothelial differentiation and in regulation of VEGF availability. Both receptor 
knock-out phenotypes are embryonically lethal in mice at E8.5 –9.0 due to gross 
vasculature abnormalities, with VEGFR-2 inactivation leading to an absence of blood 
vessel development and minimal haematopoiesis (Shalaby et al., 1995) and the 
VEGFR-1 knock-out displaying a proliferation and disorder of endothelial cells (Fong 
et al., 1995). This suggests that during embryonic development VEGFR-2 is the 
positive signal transducer, whilst VEGFR-1, plays a negative regulatory role, a 
proposal substantiated by the fact that deletion of only the tyrosine kinase domain of 
VEGFR-1 allows normal embryogenesis in mice (Hiratsuka et al., 1998), indicating 
that during development VEGFR-1 acts as a ‘VEGF sink’, regulating the availability 
of VEGF for VEGFR-2. 
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VEGFR-1 and VEGFR-2 are abundantly expressed by endothelium; although 
VEGFR-1 is expressed at a ten-fold less abundant on the cell surface than VEGFR-2. 
VEGFR-1 is also expressed by monocytes and macrophages (Clauss et al., 1990, 
Clauss et al., 1996), cells that do not produce VEGFR-2, indicating that VEGFR-1 
must function as a signalling receptor, at least in this cell type.  
 
VEGFR-1 is also expressed in soluble form and is thought to be important as a 
negative regulator of angiogenesis (Goldman et al., 1998, Lai et al., 2001). VEGFR-2 
is also present on mononuclear and endothelial progenitor cells (Lyden et al., 2001, 
Asahara et al., 1997, Asahara et al., 1999a, Asahara et al., 1999b, Gabrilovich et al., 
1998).  
 
Intracellular Signalling by VEGF 
 
Activation of VEGFR-2 is critical for VEGF-mediated angiogenic response VEGFR-
2 stimulation leads to activation of mitogen-activated protein kinases (MAPK); MEK, 
ERK-1/-2 and p38, stress activated protein kinase (SAPK), protein kinase C (PKC), 
phospholipase C (PLC) and phosphatidyl-inositol 3-kinase (PI3K), resulting in cell 
survival, proliferation, NO generation and induction of angiogenesis. VEGFR-2 
phosphorylation also induces matrix metalloproteinase expression and activation of 
focal adhesion kinase (FAK); events involved in basal lamina degradation and VEGF 
induced cell migration (Kliche and Waltenberger, 2001, Larrivee and Karsan, 2000, 
Zachary, 1998, Petrova et al., 1999).  
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VEGFR-1 function has been more elusive; it has long been known that VEGFR-1 
plays a negative regulatory role in vasculogenesis and angiogenesis. VEGFR-1 acts as 
a VEGF ‘sink’ during embryogenesis, inhibiting VEGFR-2 signalling (Hiratsuka et 
al., 1998) and also VEGFR-1 activation leads to NO release, which negatively 
regulates VEGFR-2 signalling in HUVEC (Bussolati et al., 2001). It was also shown 
that VEGFR-1 down regulates VEGFR-2 mediated endothelial proliferation via PI3-
kinase dependent pathways (Zeng et al., 2001) and additionally via sensitive G-
proteins, G-subunits, Cdc42 and partly by Rac-1(Zeng et al., 2002). In monocytes, 
VEGFR-2 is not expressed and VEGFR-1 elicits positive signals, for example, 
inducing monocyte migration to stimulus (Clauss et al., 1990). However, in 
endothelial cells positive signalling has also been reported, but in a specific ligand 
dependent manner. This has been best illustrated in porcine aortic endothelial cells 
(PAE cells) stably transfected with either human VEGFR-1 or VEGFR-2. VEGF had 
no effect on VEGFR-1 expressing cells; however PlGF (VEGFR-1-specific ligand) 
induced MAPK activation and resultant DNA synthesis in these cells. PlGF did not 
activate PLCƴ in PAER-1 cells and thus did not induce them to migrate. But, PlGF 
did up regulate plasminogen activator protein (PA) by PAER-1 cells and this did not 
occur in VEGF stimulated PAER-2 cells (Landgren et al., 1998).  
 
Vascular Endothelial Growth Factors 
 
VEGF (vascular endothelial growth factor) was identified as vascular permeability 
factor in the eighties by Senger et al.(Senger et al., 1983)  and was then identified to 
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be the same as VEGF (Leung et al., 1989). The VEGF members are basic 
glycoproteins.  
VEGFR-1 
 
VEGFR-1 is an 180kDa trans-membrane glycoprotein with seven immunoglobulin – 
like domains in the extracellular region, a single trans-membrane region and a 
consensus tyrosine kinase sequence (Shibuya et al., 1990). VEGF and PlGF stimulate 
tissue factor production and chemotaxis in monocytes (Clauss et al., 1990) 
demonstrating that VEGFR-1 acts as a functional receptor in these cell types. 
 
Pathologically, VEGFR-1 is up regulated and expressed in vessels proximal to healing 
wounds, suggesting a role in the regulation of vascular repair and maintenance (Peters 
et al., 1993). 
 
Inactivation of VEGFR-1 in mice leads to embryonic lethality at E8.5 due to 
disorganised blood vessel formation (Fong et al., 1995) suggesting a role for VEGFR-
1 in the organisation of a normal vasculature avoiding overcrowding of endothelial 
cells. VEGFR-1 has a higher affinity than VEGFR-2 for VEGF-A but has a weak 
signal transducing activity (Park et al., 1994) resulting in a regulation of VEGFR-2 by 
sequestering VEGF and controlling its presentation to VEGFR-2. 
 
The VEGFR-1 gene is alternately spliced to produce a 110kDa protein that is shorter 
and a secreted form labelled as soluble VEGFR-1 (sVEGFR-1). sVEGFR-1 is 
biologically active in dimer form (Tanaka et al., 1997). It can bind to all isoforms of 
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VEGF and PlGF and so acts as a VEGFR-2 activation regulator via VEGF (Kendall 
and Thomas, 1993). 
 
sVEGFR-1 is up regulated by hypoxia and has been found to be significantly 
expressed by the placenta (Clark et al., 1996, Helske et al., 2001). sVEGFR-1 is 
elevated in PE and removal of a sVEGFR-1 by immunoprecipitation restores the 
angiogenic balance in vitro (Ahmad and Ahmed, 2004). VEGF is also increased 
(Zeng et al., 2002). PlGF is decreased (Karumanchi and Bdolah, 2004). PE may occur 
due to loss of VEGF activity and this may partly or wholly due to an increase in 
sVEGFR-1 since adenoviral overexpression of sVEGFR-1 in pregnant rats mimics the 
clinical characteristics of PE (Maynard et al., 2003). It was shown in 1997 by Ahmed 
et al. that VEGF induces NO release which modulates angiogenesis(Ahmed et al., 
1997) and more recently AKT inhibition, which is normally phosphorylated by VEGF 
via PI3K increased sVEGFR-1 and sEng. It has been previously shown that VEGF 
induced AKT promotes NO release (Basini et al., 2007).  
 
Placental Growth Factor (PlGF) 
 
PlGF is a 149 amino acid –long protein (Kendall and Thomas, 1993). It is expressed 
in the villous trophoblasts and elevated levels are present in the murine placenta 
(DiPalma et al., 1996). In human’s PlGF is abundant in the placenta and cultured 
human umbilical vein endothelial cells (HUVEC),  
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Figure 3. Diagrammatic representation showing the interaction of the various 
angiogenic factors resulting in preeclampsia.  
During the hypoxic preeclamptic state, VEGF and PlGF protective signalling is 
compromised due to an excess of the sVEGFR-1. This is compounded by the increase 
in circulation sEng. Heme-oxygenase 1 (HO-1) has been shown to cause a decrease in 
sEng and sVEGFR-1. 
 
Soluble Endoglin (sEng) 
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Dysregulation of TGF-β signalling, an anti-inflammatory growth factor, (Robertson et 
al., 2003), which activates endothelial nitric oxide synthase (Venkatesha et al., 2006) 
have been reported in preeclamptic patients (Levine et al., 2006). Endoglin is a cell-
surface co-receptor
 
for TGF-ß1 and TGF-ß3 isoforms, and it is
 
highly expressed in 
endothelial cells and the trophoblasts. Endoglin binds to TGF-1 and reduces its 
bioavailability limiting its activity and in consequence promoting vascular 
dysfunction (Toporsian et al., 2005). A placenta-derived
 
soluble form of endoglin 
(sEng) shows anti-angiogenic effects
 
in vitro and is elevated in the circulation of 
preeclamptic
 
patients many weeks prior to clinical onset (Levine et al., 2006). Soluble 
endoglin has been shown to increase in preeclamptic patients and to be proportional to 
the increase in levels of sVEGFR-1(Stepan et al., 2007). The same study also showed 
that there was an increase also observed in IUGR patients. The molecular mechanism 
regulating sEng release has not been fully explained however HO-1 (Cudmore et al., 
2007) and angiotensin type 1 receptor antibodies (Zhou et al., 2008) have been 
observed to inhibit the release. Not many studies have considered the possible 
connection between IUGR, SGA and PE and we aimed to shed more light more on 
these groups. 
 
Heme-oxygenase (HO) 
 
Heme-oxygenase (HO) was described first by Tenhunen and Schmid in 1968 as the 
gaseous molecule involved in the catalytic breakdown of heme producing biliverdin,  
which releases carbon monoxide (CO) and iron (Fe
2+
) (Tenhunen et al., 1968). 
Although this mechanism is the major pathway for the production of CO, it had 
remained un-noticed for many years after the discovery of HO. HO being the rate 
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limiting molecule in the reaction led to researchers trying to understand the 
mechanism behind HO activity. the specific regulation of  HO-1, an inducible 
isozyme of HO, led to intense research to try to understand the system behind gene 
regulation by environmental stress. 
 
 
 
Figure 4. Schematic showing the degradation of Heme by HO in an NADPH 
dependant manner releasing CO, Fe
2+ 
and biliverdin.
 
Fe
2+
, which is cytotoxic, is 
stored by ferritin.  
 
Both HO-1 and HO-2 catalyse the identical biochemical reaction. They transform 
heme into biliverdin with
 
similar substrate specificity and co-factor requirements. In a 
comparative analysis, HO-1 and HO-2, differential
 
properties with respect to enzyme 
kinetics and substrate Km
 
values have been reported in rat as well as differences in 
apparent thermostability and immune-reactivity (Trakshel et al., 1986, Maines and 
Trakshel, 1992, Maines et al., 1986). HO-1 is inducible and responds to stress 
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whereas HO-2 is constitutively active. HO-1 is a crucial vasoprotective mediator via 
its products exhibiting antioxidant, anti-inflammatory, anti-apoptotic and anti-
mutagenic effects (Ollinger et al., 2007). A mentioned previously, Cudmore et al. saw 
a negative regulation of both sVEGFR-1 and sEng release with HO-1 knockdown in 
placental villous explants (Cudmore et al., 2007). 
Honokiol 
 
Honokiol is a biphenolic compound present in the cones, bark, and leaves of the 
Magnolia tree that has been used in the traditional Japanese medicine. Honokiol has 
been shown to have pro-apoptotic effects in a number of cancer cell lines (Chen et al., 
2011, Ahn et al., 2006). It also modulates the nuclear factor kappa B (NF-κB) 
activation pathway which is an upstream effector of VEGF. Honokiol has previously 
been shown to inhibit VEGF-D induced metastasis in a xenograft tumour model (Wen 
et al., 2009). No previous studies have been carried out regarding the potential role of 
Honokiol in preeclampsia and any studies with honokiol on endothelial cells have 
found it to inhibit vascular vessel formation of stem cell-derived endothelial cells 
(Kim et al., 2012), attenuate vascular contraction in rat aortic rings (Seok et al., 2011) 
and 5-Formylhonokiol, a derivative of honokiol exerting anti-antiogenic activity(Zhu 
et al., 2011). I aim to observe the involvement of honokiol on sVEGFR-1 and sEng 
release from HUVECs. 
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Aims and Objectives 
 
The aim is to determine the maternal and fetal circulatory levels of angiogenic factors 
in placental pathologies and to identify any differences or similarities between both 
the levels and the differing factors of in all the patient groups. 
 
We also aimed to study the effect of HO-1 and AKT on angiogenic and anti-
angiogenic factors in endothelial cells As honokiol is an inhibitor of phosphorylation 
of AKT, we hypothesise that the loss of AKT will result in an increase in sEng since 
HO-1 negatively regulates the release of sVEGFR-1 and sEng (Cudmore et al., 2007) 
and loss of AKT activity leads to an increase in sEng release (Cudmore et al., 2011). 
HO-1 loss was reported to increase sVEGFR-1 and sEng. We hypothesise that the loss 
of AKT will increase sVEGF-1 and sEng.  
 
Findings from this study could contribute considerably to the field by providing a 
clearer insight into the understandings of preeclampsia, IUGR and SGA and potential 
therapeutic agents that could be adopted to alleviate symptoms or the disorder 
altogether. 
 
 
 
 
 
Islam Afzal    
28 
 
 
 
 
 
 
 
 
 
 
 
Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
Islam Afzal    
29 
 
Clinical Data of Maternal and Fetal Samples 
 
This was a nested case-control study including pregnancies at gestation, in which 
maternal and fetal plasma sVEGFR-1, sEng, VEGF and PlGF concentrations were 
measured. Patients were recruited from a prospective population who attended the 
obstetrics department from June 2001 to June 2007 at Hospital de Maternitat, 
Barcelona. 8-12 months were spent in Barcelona collecting and processing samples 
prior to their analysis. Plasma samples were stored at - 80 °C.. The study protocol was 
approved by the Hospital Clinic Ethics Committee (see appendix i), and written 
parental consent was obtained for all study participants. 
 
The criteria of the International Society for the Study of Hypertension in Pregnancy 
were used to define PE (Brown et al., 2001). PE was diagnosed if a previously 
normotensive woman had two repeat (4h apart) diastolic blood pressure 
measurements of 90 mmHg after the 20
th
 week of gestation, together with 
proteinuria of more than 300 mg in a 24h urine specimen or at least two protein 
dipsticks in two repeat measurements (4h apart). IUGR was defined as a birth weight 
below the 10
th
 percentile for gestational age together with a Doppler pulsatility index 
(PI) in the umbilical artery above the 95
th
 percentile (Soothill et al., 1999, Baschat and 
Gembruch, 2003). Fetuses with structural or chromosomal abnormalities were 
excluded. For the purposes of this study, both IUGR and PE were early onset 
(gestational age under 32 weeks at clinical onset). The cut-off used to define early and 
late onset was chosen arbitrarily. The gestationally age-matched control group were 
identified as having had no known complications during pregnancy or at the time of 
giving birth and went into labour spontaneously with no defects or complications 
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post-delivery. Gestational age was established based on last menstrual period or early 
ultrasound evaluation (<20 weeks of gestation) in all cases (Hadlock et al., 1983). 
Other elements of the diagnosis included IUGR (<10
th
 percentile), persistent 
neurologic symptoms (headache, visual changes), oliguria (urinary output 
<500mL/24h), elevated liver enzymes greater than two times the norm and 
thrombocytopenia (<100,000 cells/µl) (2002). Deliveries were classified as SGA if 
the birthweight fell below the 10
th
 percentile of the birthweight distribution restricted 
on: completed week of gestation, year of delivery, sex of the child and parity. 
 
Statistical Analysis 
 
Results are expressed as mean ± SEM. Graphs represent the median, with the 
interquartile range demonstrated by the box. Comparisons between groups were 
performed by ANOVA for normally distributed data, respectively. 
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Tissue and Cell Culture 
 
Maintenance of primary cells and cell lines 
 
All tissue culture media and supplement were purchased sterile or filtered through a 
0.22µM pore filter. Distilled water and PBS were autoclaved before use. Tissue 
culture treated plastics were purchased sterile and all glassware was washed and 
autoclaved prior to usage. Cell culture media was stored at 4
o
C and used within 3 
months. Routine maintenance of cells was carried out in a sterile class II cabinet and 
cell cultures were maintained in a humidified incubator in 95% air and 5% CO2 at 
37
o
C. All media were supplemented with 5-10 or 20% fetal calf serum (FCS) 2mM L-
Glutamine 10U/ml penicillin and 0.1 µg/ml of streptomycin. Media was changed 
every 2-3 days and upon confluency, cells were sub-cultured. Monolayer cultures 
were washed twice with PBS and cells detached from the culture flasks by addition of 
1ml of 0.05% trypsin/0.53mM ethylenediaminetetraacetic acid (EDTA) solution for 3 
minutes. Trypsin digestion of the extra cellular matrix was inactivated by addition of 
5ml of appropriate growth media and the cell suspension was transferred to a sterile 
tube and centrifuged at 80G for 5 minutes. The supernatant was aspirated and the cell 
pellet re-suspended in growth media.  
 
Cells were re-seeded in new culture flasks at lower densities or counted using a 
haemocytometer and seeded at a specific number per 6, 24 or 96 well plate. Each time 
cells were detached with trypsin/EDTA, they were assigned an ascending passage 
number. 
Islam Afzal    
32 
 
Cell cryopreservation 
 
A reserve stock of each cell line was stored for future use by cryopreservation. T-75 
flasks containing a confluent monolayer of cells to be preserved were detached with 
trypsin/EDTA and pelleted by centrifugation prior to suspension at 1 x 106 cells/ml in 
70% FCS, 20% media with L glutamine, penicillin streptomycin and 10% dimethyl 
sulphoxide (DMSO). The cell suspension was transferred to sterile labelled cryovials 
and freezing was carried out at a rate of -1
o
C/minute in racks suspended in a vessel 
(Mr Frosty
TM
) containing 100% isopropyl alcohol. After 4 hours the cryovials were 
stored in liquid nitrogen until required. Cryopreserved cells were revived by thawing 
in a 37
o
C water bath and immediate transfer to flasks containing appropriate growth 
media. After attachment of the cells to the flask, the growth media was discarded to 
remove trace amounts of DMSO and replaced with fresh media. 
 
Details of Primary Cells and Cell Lines  
 
Human Umbilical Vein Endothelial Cell Culture (HUVEC) 
 
Human umbilical cords from obtained from normal term deliveries were washed 
thoroughly in PBS to remove all traces of blood and a 15-20 cm long section with no 
obvious clamp trauma was excised. The umbilical vein was cannulised at one end and 
flushed with PBS to remove traces of internal blood and blood clots. The cord was 
cannulised at the distal end and infused with 20 ml collagenase (1 mg/ml0 in Hanks 
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buffered saline solution (HBSS). After a 20 minute incubation at 37
o
C detached 
endothelial cells were collected by flushing the vein with medium 199 (M199) 
containing G/P/S, 20 ng/ml epidermal growth factor (EGF), 2.5 ng/ml fibroblast 
growth factor (FGF) and 20% FCS (HUVEC growth media). The cell suspension was 
centrifuged at 100G for 10 minutes and the cell pellet re-suspended in HUVEC 
growth media. Cells were seeded in flasks coated with 1% gelatine in PBS and 
allowed to attach overnight. Media was replaced to remove any contaminating 
erythrocytes and the cells grown to confluence. Cells were sub-cultured 1 in 3 upon 
reaching confluence and experiments were performed on second or third passage 
HUVEC. Experiments were carried out on HUVEC in M199 containing 5% FCS and 
G/P/S and for signalling studies and NO analysis HUVEC were rested in this medium 
overnight prior to experimentation.  
 
In-vitro Cell Function Analysis 
 
General ELISA Protocol 
 
EIA/RIA PLATES (Corning, UK) were coated with 100 l/well of capture antibody 
in PBS pH 7.4, covered with a plastic film and left in the dark at RT overnight. The 
following day the plates were washed four times with PBS containing 0.05% Tween 
(PBS-T) and then blocked for 1 hour using 200 l/well 1% BSA in PBS. After three 
PBS-T washes to remove residual BSA, samples were added at 100 l/well and plates 
were incubated for 2 hours with agitation at RT.  After washing, 100 l of 
Islam Afzal    
34 
 
biotinylated detection antibody in PBS-T was added to each well and incubated for a 
further two hours at RT with agitation. After washing streptavidin – HRP (1:200) in 
PBS-T was added for 20 minutes then washed off. The hydrogen peroxide colour 
substrate solution (RD systems, UK) was added to the plate (see manufacturer’s 
instructions), incubated until sufficient colour change was observed and the reaction 
stopped using 2M H2SO4.  Presence or absence of the protein of interest was 
determined by reading the optical density (OD) at 450 nm (adjusted at 540 nm) with a 
Multiskan Ascent 96 well plate reader and subtracting the blank value (sample 
diluents only) from the sample absorbance values. 
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Results 
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The study sought to ask the fundamental question of whether or not there was a 
difference in the levels of certain angiogenic and anti-angiogenic markers detectable 
via ELISA in both the maternal and fetal circulation. Although previous studies have 
published a difference in these markers in the maternal circulation, this has not been 
investigated in correlation with their correspondingly matched fetus to see whether 
this difference observed is also passed onto the newborn or in any way related to the 
fetal circulatory levels.  
 
Clinical Data 
 
Clinical Characteristics of the study population 
 
We analysed plasma samples from mothers and fetuses with singleton pregnancies 
recruited in the low and high-risk clinics at Barcelona’s Hospital de Maternitat 
between June 2001 and June 2007. All expectant mothers were followed 
prospectively from enrolment to delivery.  There were 48 maternal cases of the 
gestationally age matched controls,  56 PE of which 42 were actually PE, 2 were 
Eclampsia and 12 were HELLP syndrome, 25 cases of early-onset normotensive 
IUGR, 27 cases of PE + IUGR and 9 PE + small for gestational age (SGA). 
Additionally, each maternal case was matched to the delivered fetus by that patient. 
Not all maternal samples had a fetal sample and so the number of fetal were 36 
gestationally age matched controls,  12 PE, 19 cases of early-onset normotensive 
IUGR, 24 cases of PE + IUGR and 9 PE + small for gestational age (SGA). Figure 5 
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represents the differences between the studied groups and the significant differences 
in their clinical measurement of blood pressure, proteinuria and mean birth weight. In 
order to maintain an unbiased approach, samples were randomly numbered and the 
groups were not known until after analysis of the data. 
 
 
Maternal Age (yr)   32 ± 0.8         34±1.8          33±1.1        30±1.1  29 ± 1.1    29 ± 0.8     35±0.8 
Maternal Height (cm)   157±1.8       160±1.2    155±1.2        144.2±1.3           161.9±1.1          160.9±1.2   161.2±1.1 
Maternal Weight (kg)   57 ± 1.9          67.1    55±0.8        65.3±1.7              66.6±1.1           63.8 ± 3.0          63.4 ± 2.8  
Maternal BP (mmHg)* 
Systolic    118.1 ± 3.4     165.3±3.8
a
    170±1.2
 a
      170.9±7.2
 a
            124.4±2.4         127.3 ± 2.2  174.9 ± 6.3
 a
 
Diastolic    65.3 ± 1.6     102.3±2.9
a
    113±0.4
a
      106.9±7.6
a
               71.3±1.1          103 ± 2.8
a
  113.2±6.9
a
 
Proteinuria (24Hr)   126.8±12.3   2491.5±569.8
a
     2100
a
            2684.4±1141.1
a
      229.4±19.8     2214.4±489.4
a
 2520.7±730.8
a
 
Platelet Count    253 ± 15.7     168.3±18.7
a
      159±5.4
a
      80.3±15.5
a
            221.5±10.6 254 ± 16.6 177 ± 27.1
a
 
Smokers          6             7  1             3       4          6          2 
BMI     25.1±1.2      28.5±0.9        22±1.9                21.6±1.3                22.7±0.6    25.6±0.9  22.7±0.5  
Gestational Age (wk)   30 ± 0.8      31.7±0.7   29.2±0.4       31.6±0.9            30.4 ± 0.5          30 ± 0.7  30.7±1.0 
Birth weight (kg)   1.9 ± 0.2      1.7±0.2    1.1±0.8
a
       1.3±0.
7a
            0.9 ± 0.1
a
   0.9 ± 0.1
a
  1.1±0.1
a
 
 
        *Blood Pressure values represent mean of the highest recorded during pregnancy. 
        PE preeclampsia, IUGR intrauterine growth restriction, HELLP haemolysis elevated liver enzymes and low platelets, SGA small for gestational age. 
        a P<0.05 versus gestationally age matched control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Characteristics of women in the different groups and of their infants. 
Characteristic Gestationally Age Matched Control         PE Eclampsia HELLP Syndrome IUGR  PE + IUGR PE + SGA 
     n = 48           n = 42      n = 2  n = 12   n = 25       n = 27        n = 9 
Clinical Characteristics of the study Population 
 
Sandwich ELISA to detect sVEGFR-1 in human plasma 
samples 
 
Diluted plasma from the maternal cases was assayed to determine the concentations of 
sVEGFR-1. From this ELISA it was possible to conclusively state that sVEGFR-1 
was present in the human plasma samples. Figure 6 shows the concentration of 
sVEGFR-1 detected in the plasma samples in the maternal circulation at the time of 
delivery.  
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P < 0.05 
P < 0.05 
P < 0.05 
P < 0.05 
P < 0.05 
P < 0.05 
 
 
 
Figure 6. Maternal plasma concentrations of sVEGFR-1 of women in the 
different groups.  
Box and whisker plot of the anti-angiogenic factor sVEGFR-1 in mothers with 
preeclampsia alone (PE, n=42), eclampsia (n=2), HELLP syndrome (n=12), 
intrauterine growth restriction (IUGR, n=25) or PE coupled with IUGR (n=27) and 
PE coupled with small for gestational age (SGA, n=9). The bottom and top of the box 
represent the 25
th
 and 75
th
 percentile respectively and the band near the middle is the 
median. The whiskers represent the 2
nd
 and 98
th
 percentile with the outliers plotted as 
black dots. Statistical analysis; Kruksal-Wallis ANOVA followed by multiple post 
hoc Dunn’s tests.  
 
The sVEGFR-1 levels indicate that sVEGFR-1 is elevated in the preeclamptic 
maternal plasma samples (PE 2.42 ± 0.16, Eclampsia 4.18 ± 0.10, HELLP syndrome 
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3.54 ± 0.3 vs. gestationally age matched control 0.62 ± 0.04). These levels were not 
elevated in the IUGR alone compared to the control group (1.04 ± 0.12). The 
preeclamptic groups in the presence of IUGR and SGA also had significantly elevated 
levels of sVEGFR-1 (1.98 ± 0.16 and 2.4 ± 0.16 respectively). To see whether this 
difference was also present in the fetal circulation, fetal plasma samples were assayed 
and the levels of sVEGFR-1 was measured.  
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Figure 7. Plasma concentration of sVEGFR-1 present in the fetal circulation at 
delivery in the different groups.  
Box and whisker plot of the anti-angiogenic factor sVEGFR-1 in fetuses whereby 
mothers had preeclampsia alone (PE, n=12), intrauterine growth restriction (IUGR, 
n=19) or PE coupled with IUGR (PE+IUGR, n=24) or coupled with small for 
gestational age (SGA, n=9). The bottom and top of the box represent the 25
th
 and 75
th
 
percentile respectively and the band near the middle is the median. The whiskers 
represent the 2
nd
 and 98
th
 percentile with the outliers plotted as black dots. Statistical 
analysis; Kruksal-Wallis ANOVA followed by multiple post hoc Dunn’s tests. 
 
Interestingly, the concentration of sVEGFR-1 present in the fetal circulation did not 
vary at delivery in the different groups. No significant differences were found 
between all groups (PE 60 ± 3, IUGR 200 ± 40, PE + IUGR 190 ± 40, PE + SGA 60 ± 
10 VS gestationally age matched control 90 ± 10). 
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The level of sVEGFR-1 present in the plasma was expected to be elevated in the 
maternal circulation for the PE affected patients as observed in previous studies 
(Levine et al., 2004). It was apparent that the levels of sVEGFR-1 are elevated in the 
maternal circulation and not in the fetal circulation (Figure 7). The levels of sVEGFR-
1 in the PE + IUGR fetuses were not as significant as the patients suffering from a 
form of PE alone and the concentration of maternal sVEGFR-1 tended to increase 
with increasing severity of the disorder. The IUGR results for both fetal and maternal 
circulations did not show any significant differences against the gestationally age 
matched group suggesting a possible different mechanistic cause to the disorder and 
no relation to the mechanism behind PE.  
 
In order to ascertain whether the disorder was specifically due to sVEGFR-1 in 
mothers and not another anti angiogenic molecule, we assayed soluble endoglin in a 
similar manner to determine the concentration on sEng present in the maternal and 
fetal circulation. 
 
Analysis of Maternal and Fetal Plasma Samples for soluble 
Endoglin 
 
A Sandwich ELISA was used to detect sEng in human plasma samples. As with 
sVEGFR-1, sEng, capture and detection antibodies were obtained as a Duoset (R&D 
Systems). Circulation sEng levels in the plasma were detected and concentrations 
were compared to a sEng standard curve. Figures 8 and 9 present the levels of sEng 
present in the maternal and fetal circulation respectively. 
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Figure 8. Maternal plasma concentrations of soluble endoglin (sEng) of women 
in the different groups.  
Box and whisker plot of the anti-angiogenic factor soluble endoglin (sEng) in mothers 
with preeclampsia alone (PE, n=42), eclampsia (n=2), HELLP syndrome (12), 
intrauterine growth restriction (IUGR, n=25) or PE coupled with IUGR (n=27) and 
PE coupled with small for gestational age (SGA, n=9). The bottom and top of the box 
represent the 25
th
 and 75
th
 percentile respectively and the band near the middle is the 
median. The whiskers represent the 2
nd
 and 98
th
 percentile with the outliers plotted as 
black dots. Statistical analysis; Kruksal-Wallis ANOVA followed by multiple post 
hoc Dunn’s tests.  
 
The levels of the maternal plasma concentration of sEng present in the maternal 
circulation at delivery in the different groups didn’t vary as much as previous studies 
had found (Levine et al., 2006). Although there was a slight elevation in the sEng 
levels in the different preeclamptic states compared to the gestationally age matched 
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control, there was no statistical difference found (PE 3.47 ± 0.08, Eclampsia 3.62 ± 
0.06, HELLP syndrome 3.29 ± 0.1, IUGR 3.28 ± 0.11, PE + IUGR 3.58 ± 0.06, and 
PE + SGA 3.61 ± 0.09 VS Gestationally age matched control 2.67 ± 0.07). The fetal 
samples were also assayed to see if there were any differences in the fetal circulatory 
levels of sEng. 
 
 
Figure 9. Plasma concentration of soluble endoglin (sEng) present in the fetal 
circulation at delivery in the different groups.  
Box and whisker plot of the anti-angiogenic factor sEng in fetuses whereby mothers 
had preeclampsia alone (PE, n=12), intrauterine growth restriction (IUGR, n=19) or 
PE coupled with IUGR (PE+IUGR, n=24) or coupled with small for gestational age 
(SGA, n=9). The bottom and top of the box represent the 25
th
 and 75
th
 percentile 
respectively and the band near the middle is the median. The whiskers represent the 
2
nd
 and 98
th
 percentile with the outliers plotted as black dots. Statistical analysis; 
Kruksal-Wallis ANOVA followed by multiple post hoc Dunn’s tests. 
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As we expected, there was a marginal increase in the levels of sEng concentration in 
the maternal plasma samples and no significant difference in the fetal samples. The 
differences were not as large as the differences observed in the sVEGFR-1 suggesting 
that it may not alone cause the pathogenesis of preeclampsia but act secondary to 
sVEGFR-1 and enhance the pathological symptoms by creating more severe 
complications as there are more anti-angiogenic molecules present. 
 
Considering the close relationship between sVEGFR-1, VEGF and PlGF, the levels of 
VEGF and PlGF were also then measured by the same method using the same 
maternal and fetal samples to see if any correlation could be observed. 
 
Analysis of Maternal and Fetal Plasma Samples for VEGF 
 
A sandwich ELISA was used to detect VEGF in the human plasma samples. As with 
sVEGFR-1, capture and detection antibodies were obtained as a Duoset (R&D 
Systems) Circulation VEGF levels in the plasma were detected and concentrations 
were compared to a VEGF standard curve. The results indicate that there was an 
increase in the levels of VEGF in the preeclamptic states that were not complicated 
with IUGR or SGA. These levels were then reduced back to the normal levels when in 
the presence of the IUGR or SGA fetus. (PE 8.7 ± 0.66, Eclampsia 13.1 ± 0.21, 
HELLP syndrome 11.73 ± 2.17 VS gestationally age matched control 0.24 ± 0.02) 
which was not present in the PE + IUGR AND SGA groups (IUGR 0.29 ± 0.01, PE + 
IUGR 0.38 ± 0.04, PE + SGA 0.43 ± 0.14) 
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P < 0.05 
P < 0.05 
 
 
Figure 10. Maternal plasma concentrations of vascular endothelial growth factor 
(VEGF) of women in the different groups.  
Box and whisker plot of the angiogenic factor VEGF in mothers with preeclampsia 
alone (PE, n=42), eclampsia (n=2), HELLP syndrome (12), intrauterine growth 
restriction (IUGR, n=25) or PE coupled with IUGR (n=27) and PE coupled with small 
for gestational age (SGA, n=9). The bottom and top of the box represent the 25
th
 and 
75
th
 percentile respectively and the band near the middle is the median. The whiskers 
represent the 2
nd
 and 98
th
 percentile with the outliers plotted as black dots. Statistical 
analysis; Kruksal-Wallis ANOVA followed by multiple post hoc Dunn’s tests. 
 
Fetal levels were also measured to see if this increase was passed onto the fetus and 
had any effect on their circulating VEGF levels. This was not to be the case as shown 
in Figure 11 where we see fairly stable levels of VEGF in all the different groups. We 
also see that the levels were immensely decreased compared to the maternal 
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circulating levels showing that this difference is possibly tightly regulated by the 
placenta to ensure a controlled internal environment for the fetus. 
 
Figure 11. Plasma concentration of vascular endothelial growth factor (VEGF) 
present in the fetal circulation at delivery in the different groups.  
Box and whisker plot of the angiogenic factor VEGF in fetuses whereby mothers had 
preeclampsia alone (PE, n=12), intrauterine growth restriction (IUGR, n=19) or PE 
coupled with IUGR (PE+IUGR, n=24) or coupled with small for gestational age 
(SGA, n=9). The bottom and top of the box represent the 25
th
 and 75
th
 percentile 
respectively and the band near the middle is the median. The whiskers represent the 
2
nd
 and 98
th
 percentile with the outliers plotted as black dots. Statistical analysis; 
Kruksal-Wallis ANOVA followed by multiple post hoc Dunn’s tests. 
 
From this data we can deduce that the levels of VEGF in the maternal circulation 
were significantly increased in the preeclamptic states alone and not in any of the 
other groups including the PE + SGA group. The levels of VEGF present in the fetal 
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plasma samples did not differ in any of the groups in comparison to the gestationally 
matched control. 
 
Analysis of Maternal and Fetal Plasma Samples for PlGF 
 
A sandwich ELISA was adopted to detect PlGF in human plasma samples. As with 
sVEGFR-1, capture and detection antibodies were obtained as a Duoset (R&D 
Systems) and circulation PlGF levels in the plasma were detected and concentrations 
were compared to a PlGF standard curve. The figures below shows the levels of PlGF 
present in the maternal and fetal circulation. 
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Figure 12. Maternal plasma concentrations of placental growth factor (PlGF) of 
women in the different groups.  
Box and whisker plot of the angiogenic factor PlGF in mothers with preeclampsia 
alone (PE, n=42), eclampsia (n=2), HELLP syndrome (12), intrauterine growth 
restriction (IUGR, n=25) or PE coupled with IUGR (n=27) and PE coupled with small 
for gestational age (SGA, n=9). The bottom and top of the box represent the 25
th
 and 
75
th
 percentile respectively and the band near the middle is the median. The whiskers 
represent the 2
nd
 and 98
th
 percentile with the outliers plotted as black dots. Statistical 
analysis; Kruksal-Wallis ANOVA followed by multiple post hoc Dunn’s tests. 
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Figure 13. Plasma concentration of placental growth factor (PlGF) present in the 
fetal circulation at delivery in the different groups.  
Box and whisker plot of the angiogenic factor PlGF in fetuses whereby mothers had 
preeclampsia alone (PE, n=12), intrauterine growth restriction (IUGR, n=19) or PE 
coupled with IUGR (PE+IUGR, n=24) or coupled with small for gestational age 
(SGA, n=9). The bottom and top of the box represent the 25
th
 and 75
th
 percentile 
respectively and the band near the middle is the median. The whiskers represent the 
2
nd
 and 98
th
 percentile with the outliers plotted as black dots. Statistical analysis; 
Kruksal-Wallis ANOVA followed by multiple post hoc Dunn’s tests. 
 
No significant difference was found between any of the maternal groups versus the 
control (gestationally age matched control 7.91 ± 0.78, PE 3.5 ± 0.26, Eclampsia 3.32 
± 0.08, HELLP 3.55 ± 0.13, IUGR 4.38 ± 0.21, PE + IUGR 3.42 ± 0.1, PE + SGA 
2.87 ± 0.03). this was also found to be the case for the fetal samples compared to the 
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age matched control (gestationally age matched control 3.59 ± 0.11, PE 2.88 ± 0.10, 
IUGR 3.65± 0.25, PE + IUGR 3.1 ± 0.2 and PE + SGA 3.42 ± 0.01).  
 
PlGF levels decreased marginally in the maternal circulation in all the groups versus 
the gestationally matched control although it was not statistically significant. There 
was no difference in any of the groups in comparison to the gestationally matched 
control in the fetal circulation. Despite this being the case, it could have been  that the 
levels were such due to the high levels of circulating sVEGFR-1  in the preeclamptic 
states and so we tried to calculate if the sVEGFR-1 that was present was in excess or 
not.  
 
Free sVEGFR-1 presence in the plasma 
 
Concentrations of sVEGFR-1, VEGF and PlGF were obtained by sandwich ELISA as 
detailed above. PlGF binds to sVEGFR-1 with a higher affinity than VEGF. 16-20 
fold molar excess of PlGF is required to displace VEGF (Park et al., 1994). In order to 
calculate the relative concentration of free sVEGFR-1 present if any without taking 
into account the binding affinity of each molecule, we calculate how much PlGF and 
VEGF is present in the plasma and deduct the concentrations of PlGF and VEGF. One 
molecule of sVEGFR-1 binds two molecules of PlGF, VEGF or one of each. Figure 
4demonstrates the concentration of free sVEGFR-1. A value greater than 1 means 
there is a ratio where there is an excess of sVEGFR-1 present. 
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P < 0.05 
P < 0.05 
P < 0.05 
The results show that when the concentration of VEGF and PlGF is taken into account 
with the anti-angiogenic molecule sVEGFR-1, there is an excess of sVEGFR-1 
present in the preeclamptic states. 
 
 
 
Figure 14. Plasma concentration of free sVEGFR-1 present in the maternal 
circulation at delivery in the different groups.  
Box and whisker plot of the excess anti-angiogenic factor sVEGFR-1 in women with 
preeclampsia alone (PE, n=12), intrauterine growth restriction (IUGR, n=25) or PE 
coupled with IUGR and small for gestational age (SGA, n=9). The bottom and top of 
the box represent the 25
th
 and 75
th
 percentile respectively and the band near the 
middle is the median. The whiskers represent the 2
nd
 and 98
th
 percentile with the 
outliers plotted as black dots. Statistical analysis; Kruksal-Wallis ANOVA followed 
by multiple post hoc Dunn’s tests. A value greater than one represent the excess fold 
presence of sVEGFR-1 as can be observed in all the preeclamptic states. 
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The levels of free sVEGFR-1 present in the maternal plasma circulation at delivery in 
the different groups was calculated going by the levels of sVEGFR-1, VEGF and 
PlGF in each patient sample. Preeclamptic patients had significantly higher levels of 
free sVEGFR-1 levels than the IUGR alone and gestationally age matched control 
groups (gestationally age matched control 1.24 ± 0.21, PE 4.10 ± 0.62, IUGR 2.08 ± 
0.42, PE+IUGR 3.95 ± 0.76, and PE + SGA 4.8 ± 1.6). 
 
Having noticed a clear elevation in sVEGFR-1 and its correlation with preeclamptic 
mothers, we then went on to see if it were possible to somehow reduce this excess 
level of sVEGFR-1 using a knockdown of heme-oxygenase. 
 
ELISA following the Insertion of siRNA of Heme Oxygenase 
 
Heme oxygenase (HO) is an enzyme that catalyses the degradation of Heme to 
produce biliverdin, iron and carbon monoxide (CO). There are three known isoforms 
of HO. HO-1 is an inducible isoform in response to oxidative stress, hypoxia and 
cytokines. HO-2 is expressed under homeostatic conditions. Both are ubiquitously 
expressed and catalytically active. HO-3 is not active. For this reason, HO-1 and HO-
2 were tested. The effect of Heme oxygenase on sVEGFR-1 and sEng was observed 
by ELISA. HUVECs were trypsinised from T75 flasks and spun down to collect a 
pellet of cells. The supernatant was discarded and the cells were re-suspended in 
100µl of a siRNA solution and pipette into an AMAXA chamber ensuring the 
suspension was between the metal contacts. The chamber is then placed into the 
AMAXA machine and allowed to insert the siRNA into the cells. The suspension is 
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then aspirated and placed into a new gelatinised T75 along with EBM HUVEC 
medium and incubated for 24hours. After 24 hours, cells were trypsinised and plated 
at a density of 1 x 10
5
 cells per well in Medium M199 20% FCS along with L-
glutamine, Pen/Strep, upon a gelatinised 24 well plate and incubated for a further 24 
hours. The HUVECs were then washed twice in PBS and re-incubated in M199 
5%FCS with various growth factors and then incubated for 24 hours. Medium was 
collected the next day and frozen at -80
o
C prior to assaying. An ELISA was prepared 
by coating the 96-well plate with capture antibody (R&D systems) and detecting 
using the sVEGFR-1 detection antibody (R&D systems). Concentrations were 
calculated by comparison to a standard curve to sVEGFR-1 on the same plate as the 
samples. 
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P < 0.05  
 
 
 
 
 
 
 
Figure 15. Bar chart showing the levels of anti-angiogenic factor sVEGFR-1 
detected by ELISA in human umbilical vein endothelial cells following siRNA 
knockdown of heme-oxygenase 1 (HO-1) and following 24 hour treatment with 
VEGF.  
VEGF alone did not cause a significant increase in sVEGFR-1 in the control 
compared to the mismatch but did cause a large release when HO-1 was knocked 
down showing VEGF induced sVEGFR-1 release is regulated by HO-1 (significance 
measured by T-test where P<0.05, n=3). 
 
Following the administration of VEGF to the HUVECS, we saw a markedly increase 
in sVEGFR-1 release in the HO-1 siRNA sample compared to the mismatch control 
when there was no siRNA present for HO-1 (Control MM 25.89 ± 0.35, control HO-1 
31.94 ± 1.07, MM VEGF  35.51 ± 0.28, HO-1 + VEGF 58.97 ± 0.14, n=3).  
 
HO-1 seems to be causing an increase in the levels of sVEGFR-1 present in the 
medium collected from the stimulated HUVECs. To see whether this was specific to 
HO-1 alone or also by HO-2 we carried out the same test with an siRNA knockdown 
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of HO-2 and analysed the data to see if any obvious difference could be observed as 
were with HO-1. A Mismatch (MM) was used as a control.  
 
Figure 16. Bar chart showing the levels of anti-angiogenic factor sVEGFR-1 
detected by ELISA in human umbilical vein endothelial cells following siRNA 
knockdown of heme-oxygenase 2 (HO-2) and following 24 hour treatment with 
VEGF.  
VEGF alone did not cause a significant increase in sVEGFR-1 in both the control nor 
the VEGF induced sVEGFR-1 release, compared to the mismatch control 
(significance measured by t-test, n=3). 
 
The concentration of sVEGFR-1 detected following siRNA knockdown of HO-2 and 
stimulation with VEGF for 24hours caused no significant difference to the amount of 
sVEGFR-1 released by the HUVECS (Control MM 25.89  ± 0.35, control HO-2 29.19 
± 0.68, MM VEGF  35.51 ± 0.28, HO-2 + VEGF 35.43 ± 0.14, n = 3). 
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P < 0.05 
HO-2 did not seem to be causing any significant changes in comparison to HO-1. 
When both HO-1 and HO-2 were used together, the results were similar to the results 
observed by HO-1 and so it seems that the effect was primarily caused by HO-1 and 
not HO-2 as demonstrated in Figure 17 (Control MM 25.89 ± 0.35, control HO-1 + 
HO-2 34.03 ± 0.5, and MM VEGF  35.51 ± 0.28, HO-1 + HO-2 + VEGF 61.26 ± 
0.21, n = 3). 
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Figure 17. Bar chart showing the levels of anti-angiogenic factor sVEGFR-1 
detected by ELISA in human umbilical vein endothelial cells following siRNA 
knockdown of heme-oxygenase 1  and heme-oxygenase 2 (HO-1 and HO-2) and 
following 24 hour treatment with VEGF.  
VEGF alone did not cause a significant increase in sVEGFR-1 in the control 
compared to the mismatch but did cause a large release when HO-1 and HO-2 were 
knocked down showing VEGF induced sVEGFR-1 release is regulated predominantly 
by HO-1 and not by HO-2  (significance measured by t-test, n=3). 
 
The effect of Honokiol on sVEGFR-1 and sEng release 
 
Honokiol, an extract from the cone, bark and leaves of the magnolia tree has been 
found to be anti tumourigenic and have potential therapeutic applications since it has 
been found to be a modulator of the NFκB pathway which is an upstream effector of 
VEGF and has also been found to inhibit phosphorylation of Akt. We wanted to see if 
honokiol had any effect on sVEGFR-1 and whether it could be potentially used 
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therapeutically to alter the increased levels of sVEGFR-1 in the preeclamptic state. 
We first wanted to see if this would have any effect on the sVEGFR-1 and sEng 
release on HUVECs and so, similar to the siRNA treatment with HO-1, cells were 
pretreated with Honokiol for 24 hours and then an ELISA was carried out to see if 
sVEGFR-1 and sEng levels were affected. 
 
HUVECs were incubated with Honokiol firstly at differing concentrations to 
determine a dose dependant response and then at 2 differing concentrations (2µg/ml 
and 20 µg/ml) and then added various growth factors to see if Honokiol had any effect 
on VEGF induced sVEGFR-1 and sEng release. 
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P < 0.05 
P < 0.05 
P < 0.05 P < 0.05 
 
 
 
 
 
 
 
 
 
Figure 18. Bar chart showing the dose dependant decrease in sVEGFR-1 release 
from HUVECs following treatment with honokiol.  
Levels of sVEGFR-1 decrease the higher the concentration of honokiol particularly 
from  1.0-20µg/ml (statistical analysis was carried out using t-test n=3). 
 
Following the observation in Figure 18 where we see that honokiol does indeed 
decrease sVEGFR-1 release from HUVECS (Control 33.97 ± 0.45, Honokiol 0.1 
34.58 ± 0.19, Honokiol 1.0 33.77 ± 0.65, Honokiol 5.0 23.88 ± 0.19, Honokiol 10 
16.84 ± 0.84, Honokiol 20 18.4 ± 0.93, VEGF 41.04 ± 0.92, VEGF + Honokiol 0.1 
37.23 ± 1.39, VEGF + Honokiol 1.0 22.59 ± 0.6, VEGF + Honokiol 5.0 16.52 ± 0.8, 
VEGF + Honokiol 10 11.37 ± 0.72, VEGF + Honokiol 20 10.93 ± 0.33, n=4), we then 
went on to see if it has an effect on sEng release at two particular concentrations, 
namely 2µg/ml and 20µg/ml since we observed an effect in sVEGFR-1 release at 
these doses. 
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Figure 19. Bar chart showing the dose dependant increase in sEng release from 
HUVECs following 24 hour treatment with honokiol and then a one hour 
treatment with various growth factors.  
Levels of sEng increase the higher the concentration of honokiol particularly in the 
presence of VEGF, Interferon γ, basic FGF and TNFα (statistical analysis was carried 
out using t-test n=3). 
 
Different growth factors were also used to see if these also had any effect on sEng 
release. The HUVECS were pretreated with VEGF(VEGF), Interferon ƴ (IFN), basic 
fibroblast growth factor (bFGF) and tumour necrosis factor α (TNF) since these have 
previously been shown to have an effect on sEng release (control 1104.3 ± 152.6, 
Honokiol 2 1363.2 ± 163.4, Honokiol 20 2087 ± 120.4, VEGF 934 ± 153.9, VEGF + 
Honokiol 2 1339.8 ± 177.3, VEGF + Honokiol 20 2023 ± 116.8, IFN 1339.3 ± 177.3, 
IFN + Honokiol 2 1512.7 ± 127.3, IFN + Honokiol 20 1867.5 ± 107.8, bFGF 1139.3 
± 165.7, bFGF + Honokiol 2 1358.6 ± 178.4, bFGF + Honokiol 20 1954.5 ± 112.8, 
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TNF 1168.8 ± 167.4, TNF + Honokiol 2 1118.3 ± 164.5, TNF + Honokiol 20 1487.6 
± 185.9, n=4). The results varied significantly but demonstrated a dose dependant 
increase in the sEng release which was attenuated in the presence of the growth 
factors. 
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Conclusion 
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Conclusion 
 
Various angiogenic growth factor levels were measured in human plasma collected at 
time of delivery from both maternal and fetal patients to examine a possible 
relationship between the concentrations and the pregnancy specific disorders of 
preeclampsia IUGR and SGA and were compared to their gestationally age matched 
control. The findings confirmed as found in previous studies that concentrations of 
sVEGFR-1, which were previously reported to be increased in women with 
established preeclampsia (Maynard et al., 2003) begin to show an increase with 
increased severity of the clinical disease from preeclampsia through to eclampsia and 
eventually to HELLP syndrome. With the increase in the sVEGFR-1 level, there was 
an overall excess of sVEGFR-1 in the preeclamptic states which was not present in 
the gestationally age matched control suggesting that the increase in these factors may 
be attributable in part to binding by sVEGFR-1 to VEGF and PlGF causing an anti-
angiogenic effect. Women with preterm preeclampsia and a small-for-gestational-age 
infant had higher sVEGFR-1 levels, which is consistent with previous studies. (Taylor 
et al., 2003, Levine et al., 2004).  
 
sVEGFR-1 
 
Normal placental conditioned media promoted angiogenesis and pre-incubation with 
media containing exogenous sVEGFR-1 significantly attenuated cell migration and 
tube formation whereas this addition to preeclamptic conditioned media had no 
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further effect on angiogenesis due to saturating concentrations of sVEGFR-1 (Ahmad 
and Ahmed, 2004). 
 
An imbalance in circulating angiogenic factors is emerging as a prominent 
mechanism that mediates the endothelial dysfunction and the clinical signs and 
symptoms of preeclampsia. sVEGFR-1, an endogenous anti-angiogenic factor that is a 
potent VEGF antagonist, is elevated 4-fold in the maternal circulation of preeclamptic 
patients and increased with severity of the disorder. Although there was a trend to 
show an increase with severity, it should be highlighted that due to the low number of 
patients in the eclamptic and HELLP syndrome categories, it would not be 
appropriate to make a definite conclusion on this basis until a further insight is made 
into this trend. The fetal circulation remained stable suggesting the sVEGFR-1 is 
released on the maternal side of the placenta and doesn’t pass through the 
maternal:fetal barrier. 
 
Soluble Endoglin 
 
We did not see any significant increase from the preterm control although it did show 
an increasing trend and as the Stepan et al paper found, the level of sEng found in 
IUGR patients was marginally lower than the PE patients (Stepan et al., 2008). IUGR 
and PE both occur due to an impaired placental function including poor trophoblast 
invasion. This study clearly defined IUGR patients as a fetus below a certain weight 
percentile due to a placental insufficiency and clearly distinguished between SGA 
fetuses which include healthy fetuses with a low genetic growth potential. The 
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slightly elevated levels of sEng in this study may suggest that it is partially involved 
in the pathology of IUGR this would concur with the idea that sEng induces in vivo 
vascular permeability and PE typical symptoms, including hypertension. It is not 
possible to conclude whether sEng is produced in response to an increase in sVEGFR-
1, vice versa or independent of each other via a different mechanism. The data 
supports previous findings that there is not an increase in sVEGFR-1 concentrations 
in IUGR (Shibata et al., 2005, Wathen et al., 2006). Although some studies have 
shown an increase in sVEGFR-1 in IUGR patients (Tsatsaris et al., 2003, Wallner et 
al., 2007, Stepan et al., 2004), they do not exclude that some of the IUGR patients 
would have developed PE later on and confirm that some IUGR pregnancies were 
close to the threshold of PE symptomatic criteria whereas our samples were collected 
upon delivery. 
 
With regards to the PE + SGA samples, unfortunately SGA alone samples were not 
available at the time of the study and so comparisons can’t be drawn against it.  The 
only comparisons that can be made are in comparison to the PE alone states and PE + 
IUGR allowing an insight into whether PE itself was causing a difference or the fetus 
seeing as the two disorders differ little in terms of the fetal effect. This allows us to 
make a more critical conclusion on the placenta alone and eliminate the possibility of 
a “fetal burden” causing an overload effect on the maternal circulation or upon the 
placenta for nutrition. 
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VEGF 
 
VEGF is not only important in angiogenesis, but also in maintaining endothelial 
health including the formation of endothelial fenestrae (a hallmark of the glomerular 
vascular endothelium). sVEGFR-1 overexpression in animals induces glomerular 
endotheliosis with the loss of endothelial fenestrae that resembles the renal 
histological lesions of preeclampsia. More severe forms of preeclampsia, including 
the HELLP syndrome, may be explained by a concomitant elevation in both 
sVEGFR-1 and soluble endoglin, another anti-angiogenic factor. Angiotensin II plays 
multiple roles in the pathology of pre 
eclampsia, including contributing to hypertension, increasing oxidative stress via 
production of superoxide anions, and activating platelets (Shah, 2005). The study 
showed that the VEGF levels only increased in the maternal circulation of the PE 
alone states and not in the presence of IUGR or SGA. It may be that the IUGR and 
SGA conditions are causing VEGF levels to return to normal via a mechanism that is 
hindered by PE alone but it is not possible to conclude such a theory without further 
investigation. It could be that VEGF is produced in excess to flatten the imbalance of 
VEGFR-1:VEGF in the maternal circulation but again, it is not clear enough to 
conclude. Previous studies have also found that VEGF is elevated in PE states (Lam 
et al., 2005) but since VEGF is bound with high affinity to sVEGFR-1 in PE, the 
overall result is still an excess of sVEGFR-1. serum
 
VEGF is unlikely to serve as a 
useful screening marker until
 
ELISA kits that are sensitive enough to detect single-
digit
 
picogram concentrations with high reliability become available (Thadhani et al., 
2004, Taylor et al., 2003). VEGF loss must be due to a loss of AKT since a loss of 
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AKT results in an increase of sVEGFR-1 and sEng (Cudmore et al., 2011) and it must 
be a maternal loss of AKT  since fetal levels remain stable. 
 
PlGF 
 
Many studies have shown PlGF levels to be low in PE serum (Maynard et al., 2003, 
Tsatsaris et al., 2003, Levine et al., 2004) probably due to it being bound to sVEGFR-
1 rather than a decreased production by the placenta, PlGF has been shown to slowly 
increase in the first stages of pregnancy and then steadily decline (Reuvekamp et al., 
1999). Seeing as PE symptoms are prevalent in the latter stages of pregnancies, it may 
be that the PlGF levels are decreasing due to the increase presence of sVEGFR-1. 
Decreased levels of urinary PlGF during mid-gestation predict subsequent 
development of clinical preeclampsia (Levine et al., 2005). 
 
Physiologically, the antagonism of VEGF and PlGF as a mechanism involved in the 
pathogenesis of preeclampsia is consistent with what is known about the disease. The 
placenta produces sVEGFR-1 in high amounts in preeclampsia; free VEGF and PlGF 
are respectively low. In fact, sVEGFR-1 concentrations are high 5-6 weeks prior to 
the onset of clinical disease and concentrations of free VEGF and PlGF are also found 
to be low prior to clinical preeclampsia (Chen et al., 2009).  
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Free VEGFR-1 
 
Previous studies have suggested that there is an increase in sVEGFR-1 in PE patients 
most notably Rajakumar et al who looked at peripheral blood mononuclear cells and 
an increase in sVEGFR-1 production under hypoxia (Rajakumar et al., 2005). This 
study calculated directly that there is an excess of sVEGFR-1 in all the PE states 
independent of IUGR and SGA further supporting the idea that sVEGFR-1 is the 
underlying factor with this disorder. It also provides a definite concentration of how 
much excess is produced and how much of a fold increase there is compared to the 
preterm control. The data calculations were ensured to be done per patient before any 
comparable means were interpreted in order to ensure a clearer result to demonstrate 
the excess is across the scale and not dependent on outliers assisting the calculation to 
provide a clearer spread of data. 
 
While it is not clear what is causing the excess sVEGFR-1 production the data does 
leave us with several unanswered questions including what is causing the maternal 
pro-inflammatory state considering the same is not happening in the paired fetal 
circulations? PE is a placental disorder and so the maternal inflammatory response 
must be by the placenta, and more on the maternal side of the placenta. This study 
excludes the fetal involvement seeing as it is not happening in IUGR and SGA 
doesn’t affect the excess increase of sVEGFR-1 in the maternal circulation. 
 
Our study had limitations. We found the sVEGFR-1 levels in women with established 
preeclampsia to be higher than others have reported them to be. Longer freezer-
storage times may have resulted in decreased sVEGFR-1 levels in their studies 
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(Levine et al., 2004, Maynard et al., 2003). A more likely explanation is that the 
women in our study may have had more severe preeclampsia. The mean gestational 
age of the fetus at the time when specimens were obtained from women with clinical 
preeclampsia was 30 weeks in this study, as compared with 34-38 weeks or less in 
other studies (Maynard et al., 2003) 
Heme-oxygenase 
 
We saw an elevation of sVEGFR-1 by VEGF following knockdown by HO-1 siRNA 
and not by HO-2 in HUVECs. This complies with previous studies that have seen 
HO-1 decreased and sVEGFR-1 levels increased in PE placenta (Ahmad and Ahmed, 
2004, Zhou et al., 2002). Our group has also previously showed that adenoviral over-
expression of HO-1 in endothelial cells inhibited VEGF mediated sVEGFR-1 release 
(Cudmore et al., 2007) and inhibition of HO-1 caused sVEGFR-1 levels to increase. 
Although the same effect was not seen with HO-2, Knockdown of HO-2 has been 
shown to reduce Akt phosphorylation in vivo (Turkseven et al., 2007)and an inter-
dependency between Akt-1 and HO-1 has been shown by our group recently 
(Cudmore et al., 2011).  
 
Honokiol 
 
The experimental data showed that sVEGFR-1 levels decreased with increasing 
concentration of Honokiol past 0.1µg/ml. No current studies have been done to show 
the effect of Honokiol on sVEGFR-1 levels providing it a potential therapeutic agent 
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for PE. Although honokiol is an inhibitor of the phosphorylation of Akt and so we 
hypothesised that it would increase the release of SVEGFR-1, it decreased it. It is 
likely that honokiol is exerting its effect by some other signalling pathway, which has 
not yet been fully investigated. Interestingly sEng levels were elevated with 
increasing concentrations of honokiol as we expected suggesting maybe sVEGFR-1 
and sEng work by different mechanism and although this agent is yet to be fully 
investigated there may still be some positive progress with this drug.  
 
Unfortunately due to time restrictions the experiments with heme oxygenase and 
Honokiol were not further investigated to see if they would have any further effects 
particularly on PE patient samples, possibly as a quencher of sVEGFR-1. 
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Clinical Application 
Once a predictive biomarker has been established and is commercially and available 
for the diagnosis of early-onset preeclampsia, pregnant woman at risk of developing 
PE could be stabilised with statins. Statins may alleviate symptoms of PE since they 
inhibit cytokine – mediated sVEGFR1 release in placental explants (Cudmore, 2007). 
Low dose aspirin only mildly reduces the risk of future PE in high risk mothers (Ofori 
2007). New methods of treatment either by inducing HO-1 activity or reducing 
sVEGFR-1 and sEng may have therapeutic potential and in turn prolong pregnancy in 
early onset PE, resulting in a decreased burden upon both mother and fetus (Ahmed 
2011). The world’s first randomised placebo-controlled trial, StAmP (Statins to 
Ameliorate Early Onset Preeclampsia) will inform medical practitioners whether 
statins are viable in PE. 
 
This would seriously improve outcomes for mothers and foetuses globally and 
decrease the negative impact PE has on both.  
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Future Work 
 
 With more time and resources it would have been interesting to test the samples for a 
number of other possible markers including the possible implication of Ang II as a 
possible release mechanism for sVEGFR-1 in pregnancy. Ang II stimulates sVEGFR-
1 production in a dose- and time-dependent manner from human villous explants and 
cultured trophoblasts but not from endothelial cells, suggesting that trophoblasts are 
the primary source of sVEGFR-1 during pregnancy (Zhou et al., 2007). This has not 
been investigated in actual serum from patients and could be a potential diagnostic 
marker.  
 
Since this research was carried out, a number of research groups have carried out 
similar studies and so a lot of research has gone into this disorder leading to many 
advances and insight into the complications involved in preeclampsia and IUGR. 
 
Selenium was found to be lower in patients with preeclampsia than controls. Since 
selenium is an antioxidant it raises the interesting the question of whether a small 
increase in selenium intake might help prevent preeclampsia in susceptible women 
(Rayman et al., 2003) 
 
Most notably the involvement of HO-1 and its metabolite carbon monoxide (CO) in 
preeclampsia, inhibiting the release of sVEGFR-1 and sEng. Although animal models 
have been made to show the positive effects of HO-1 and CO, due to the risk of it 
being moved forward to clinical trial, none has been done yet until further research is 
carried out. Women with preeclampsia exhale less CO than normal pregnant women 
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suggesting preeclampsia may be due to a loss of HO-1 activity (Ahmed, 2011). 
Following on from this in April 2012 our group started a Phase II clinical trial 
(StAmP) into the potential role of pravastatin ameliorating early onset preeclampsia 
due to pravastatin increasing HO-1 expression and down-regulating tissue factor 
expression in monocytes and trophoblasts, preventing placental damage (Ahmed, 
2011). 
 
It would be beneficial to understand the intracellular signalling pathway involved with 
HO-1 to cause the decrease in sVEGFR-1 as possible drug targets in the future.  
 
Unfortunately at the time of the completion of this thesis, Uterine artery Doppler 
results were not available. It may be a method that could be adopted by physician in a 
clinical setting if they see any significant measurable differences between PE or 
IUGR groups versus controls (see appendix ii).  
 
A reliable animal model of IUGR does not exist at the moment without surgical 
intervention but could be developed to provide a better understanding of it since our 
current data shows there may be a different mechanism involved. 
 
It is my opinion that preeclampsia could possibly be a genetic condition or have a 
genetic link triggered by environmental factors. A gene array of preeclamptic patients 
versus IUGR SGA and controls would allow us to observe any differences. Dietary 
deficiencies may be another cause and so could be observed. Wallis et al found that 
preeclampsia rates increased by nearly 25 % in between 1987 and 2004 in the USA 
(Wallis et al., 2008). 
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Further research on the role and mechanisms regarding the early diagnosis and 
treatment of PE and the reduction of sVEGFR-1 would help in the development of 
clinical benefits both during PE and in the future for both mother and fetus after birth. 
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Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Test 
Gestationally Age Matched 
Control PE Eclampsia 
HELLP 
syndrome IUGR 
PE + 
IUGR 
PE + 
SGA 
        
Aspartate aminotransferase U/L 25 66 112 193 21 48 29 
Alanine aminotransferase U/L 25 76 78 188 21 46 37 
Lactate dehydrogenase U/L 165 573 84 1025 275 566 459 
1 minute Apgar score 8 8 6 7 8 6 8 
5 minute Apgar score 9 9 8 9 9 9 10 
Umbilical artery pH 7.26 7.24 N/A 7.25 7.18 7.20 7.20 
Umbilical vein pH 7.33 7.29 7.20 7.29 7.26 7.26 7.27 
Z Umbilical artery PI -0.26 1.37 1.50 5.58 12.87 11.96 0.28 
Z Uterine artery mean PI 0.40 4.25 N/A 5.80 4.47 5.41 4.07 
Z Middle cerebral artery PI -0.11 
-
1.05 N/A -1.89 -2.76 -2.03 -1.47 
Z Cerebro placental ratio 0.15 
-
1.75 N/A -2.45 -3.66 -3.17 -0.41 
 
 
Appendix ii. Clinical data collected during pregnancy of the different states of expectant mothers.  
Preeclampsia; PE. Hemolysis, elevated liver enzymes, low platelets; HELLP. Intrauterine growth restriction; IUGR. Small for gestational age; 
SGA.  
 
